- Home
- ADXN vs CLRB Comparison
ADXN vs CLRB Comparison
Compare ADXN & CLRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ADXN | CLRB |
|---|---|---|
| Founded | 2002 | 2002 |
| Country | Switzerland | United States |
| Employees | 2 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.1M | 12.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ADXN | CLRB |
|---|---|---|
| Price | $8.23 | $3.81 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 8.1K | ★ 70.4K |
| Earning Date | 12-04-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $198,824.00 | N/A |
| Revenue This Year | $86.57 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.51 | $2.71 |
| 52 Week High | $12.05 | $45.90 |
Technical Indicators
Market Signals| Indicator | ADXN | CLRB |
|---|---|---|
| Relative Strength Index (RSI) | 48.83 | 57.23 |
| Support Level | $7.59 | $3.30 |
| Resistance Level | $8.99 | $3.15 |
| Average True Range (ATR) | 0.52 | 0.29 |
| MACD | 0.05 | 0.14 |
| Stochastic Oscillator | 50.97 | 95.43 |
Price Performance
Historical ComparisonAbout ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.